Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.98p
   
  • Change Today:
      0.000p
  • 52 Week High: 3.40
  • 52 Week Low: 0.68
  • Currency: UK Pounds
  • Shares Issued: 427.35m
  • Volume: 101,998
  • Market Cap: £4.17m

Theracryf Overview

TheraCryf is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.

Key Personnel

CEO: Huw Jones
CFO: Toni Hänninen
Independent Non-Executive Director: Alan Barge
Interim Chairman: Susan (Sue) Foden
Non-Executive Dir:

Contact Details

Address: Liverpool Science Park Innovation Centre 2, 146 Brownlow Hill, Liverpool, Merseyside, United Kingdom , L3 5RF
Website: http://www.theracryf.com/

Listings

Sector: Pharma and Biotech(LSE)
Index: FTSE AIM All-Share
ISIN: GB00BSVYN304

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Theracryf Market Data

Currency UK Pounds
Share Price 0.98p
Change Today 0.000p
% Change 0.00 %
52 Week High 3.40
52 Week Low 0.68
Volume 101,998
Shares Issued 427.35m
Market Cap £4.17m

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
40.15% below the market average40.15% below the market average40.15% below the market average40.15% below the market average40.15% below the market average
52.94% above the sector average52.94% above the sector average52.94% above the sector average52.94% above the sector average52.94% above the sector average
Price Trend
88.62% below the market average88.62% below the market average88.62% below the market average88.62% below the market average88.62% below the market average
58.49% below the sector average58.49% below the sector average58.49% below the sector average58.49% below the sector average58.49% below the sector average
Income Not Available
Growth
19.83% below the market average19.83% below the market average19.83% below the market average19.83% below the market average19.83% below the market average
48.57% below the sector average48.57% below the sector average48.57% below the sector average48.57% below the sector average48.57% below the sector average

Theracryf Dividends

No dividends found

Trades for 17-Jun-2024

Time Volume / Share Price
15:48 101,522 @ 0.99p
14:32 476 @ 0.90p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page